Wall Street brokerages expect VBI Vaccines Inc (NASDAQ:VBIV) to report earnings per share of ($0.06) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for VBI Vaccines’ earnings, with estimates ranging from ($0.07) to ($0.05). VBI Vaccines reported earnings per share of ($0.28) in the same quarter last year, which would indicate a positive year over year growth rate of 78.6%. The business is expected to issue its next quarterly earnings report on Monday, February 24th.
According to Zacks, analysts expect that VBI Vaccines will report full-year earnings of ($0.47) per share for the current year, with EPS estimates ranging from ($0.48) to ($0.45). For the next financial year, analysts anticipate that the company will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.21) to ($0.15). Zacks’ EPS calculations are an average based on a survey of research analysts that follow VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). VBI Vaccines had a negative return on equity of 70.54% and a negative net margin of 1,458.97%. The business had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.90 million.
Several research firms have commented on VBIV. Raymond James began coverage on shares of VBI Vaccines in a report on Thursday, November 14th. They issued an “outperform” rating and a $3.00 target price on the stock. Zacks Investment Research lowered shares of VBI Vaccines from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $3.81.
VBIV stock traded down $0.04 during mid-day trading on Wednesday, hitting $0.82. The stock had a trading volume of 3,461,023 shares, compared to its average volume of 1,686,317. The company has a current ratio of 1.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01. VBI Vaccines has a 52 week low of $0.47 and a 52 week high of $2.20. The firm has a market capitalization of $160.13 million, a P/E ratio of -0.85 and a beta of 0.79. The firm has a fifty day simple moving average of $0.63 and a 200 day simple moving average of $0.88.
In related news, major shareholder Perceptive Advisors Llc purchased 20,000,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were bought at an average cost of $0.50 per share, with a total value of $10,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jeff Baxter purchased 150,000 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The shares were bought at an average cost of $0.50 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 608,255 shares in the company, valued at approximately $304,127.50. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 30,212,000 shares of company stock worth $15,105,440. Insiders own 10.50% of the company’s stock.
Several institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can grew its holdings in shares of VBI Vaccines by 71.8% during the 2nd quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 15,717 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of VBI Vaccines during the 2nd quarter valued at approximately $25,000. Citadel Advisors LLC bought a new stake in shares of VBI Vaccines during the 2nd quarter valued at approximately $31,000. Susquehanna International Group LLP bought a new stake in shares of VBI Vaccines during the 2nd quarter valued at approximately $58,000. Finally, Weil Company Inc. grew its holdings in shares of VBI Vaccines by 228.6% during the 2nd quarter. Weil Company Inc. now owns 71,875 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 50,000 shares during the last quarter. 40.91% of the stock is currently owned by institutional investors.
About VBI Vaccines
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Further Reading: What is the Russell 2000 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.